BioCryst Pharmaceuticals Achieves Significant Reimbursement Milestone
BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) has made a significant stride in the healthcare market by securing reimbursement for ORLADEYO (berotralstat) across major European nations. This breakthrough follows a positive recommendation from the Zorginstituut Nederland, leading to ORLADEYO's approval for the routine prevention of hereditary angioedema (HAE) attacks for patients aged 12 years and older.
The reimbursement approval in the Netherlands is a landmark achievement that means patients across Europe can access the first oral, once-daily preventive therapy specifically designed for hereditary angioedema. Abid Karim, the general manager of Europe at BioCryst, expressed pride in this accomplishment, noting that it enhances the availability of modern treatment options for HAE patients.
Understanding ORLADEYO and Its Impact
ORLADEYO (berotralstat) is the first and only oral therapy aimed specifically at preventing HAE attacks, available for both adults and pediatric patients age 12 and older. Taken as a single capsule once daily, ORLADEYO works effectively by decreasing plasma kallikrein activity, a key factor in the occurrence of HAE attacks.
This revolutionary treatment was approved after the European Commission granted marketing authorization in April 2021. Since then, ORLADEYO has been made commercially available in over 30 countries, and this recent reimbursement approval further establishes its accessibility for patients in need.
Safety and Efficacy Information
While ORLADEYO has shown to be effective as a preventative measure against HAE attacks, it's crucial to note that its safety and efficacy for treating acute HAE attacks have not been established. It is not intended for acute attack treatment, and dosages exceeding 150 mg once daily are not recommended. Notably, an increase in QT prolongation risk is observed with higher dosages, emphasizing the importance of adhering to prescribed guidelines.
Common adverse reactions include abdominal discomfort, vomiting, diarrhea, back pain, and gastroesophageal reflux disease. Individuals with moderate to severe hepatic impairment should be monitored more closely, as a reduced dosage of 110 mg once daily is suggested for these patients.
The Vision Behind BioCryst Pharmaceuticals
BioCryst is a dedicated global biotechnology company focused on innovating treatments for rare diseases like hereditary angioedema. The company's commitment is evident in their approach to drug development, harnessing their expertise in structure-guided drug design to create first-in-class therapies.
With ORLADEYO being a flagship product, BioCryst continues to advance its research pipeline, looking to bring forward additional therapeutic options that target challenging health conditions. Their mission goes beyond simply commercializing a product; it aims to significantly enhance the lives of those affected by rare diseases and provide hope in areas of unmet medical need.
Frequently Asked Questions
What is ORLADEYO and how does it work?
ORLADEYO (berotralstat) is an oral medication designed to prevent hereditary angioedema attacks by inhibiting plasma kallikrein, reducing the likelihood of HAE episodes in patients aged 12 and older.
Which countries have approved reimbursement for ORLADEYO?
As of now, ORLADEYO has received reimbursement approval in all major European countries following its acceptance in the Netherlands.
What are the side effects associated with ORLADEYO?
The most common side effects reported include abdominal pain, vomiting, diarrhea, and back pain. Patients should consult their healthcare providers regarding potential reactions.
How should ORLADEYO be taken?
ORLADEYO is taken once daily in a single capsule form, with or without food. Adherence to the prescribed dosage is essential for optimal efficacy.
Who is eligible to use ORLADEYO?
ORLADEYO is approved for individuals aged 12 years and older. The safety and efficacy in children under 12 have not yet been established.
